19 Results for "

viral maturation

" in MedChemExpress (MCE) Product Catalog:
Products (19)

19 Results for "viral maturation" in MCE Product Catalog:

20
20 Publications Verification
Cat. No.: HY-111964
CAS No.: 2189684-44-2
Purity:  98.44%
Synonyms: GS-6207
Target:  

HIV

Research Areas:  

Infection

Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
loading...
    loading...
20
20 Publications Verification
Cat. No.: HY-111964A
CAS No.: 2283356-12-5
Synonyms: GS-6207 sodium
Target:  

HIV

Research Areas:  

Infection

Lenacapavir (GS-6207) sodium is an HIV-1 capsid inhibitor. Lenacapavir sodium binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir sodium exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir sodium is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0842
CAS No.: 174022-42-5
Synonyms: PA-457; MPC-4326; YK FH312
Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0620
CAS No.: 102841-43-0
Mulberroside C is one of the main bioactive components in white mulberry (Morus alba L.). Mulberroside C exhibits antiplatelet, antiviral and neutrophil-regulating activities, and binds to EV-A71 VP1 with a Kd value of 1.289 nM. Mulberroside C reduces the phosphorylation level of ERK, promotes the phosphorylation of IP3RI at the Ser 1756 site, and decreases calcium influx and calcium mobilization. Mulberroside C inhibits the expression of P-selectin (P-selectin). Mulberroside C upregulates the cyclic nucleotide signaling pathway in human platelets. Mulberroside C binds to IL-23R, upregulates the expression of G-CSF, GM-CSF and RASGRP1, and activates the RAS/ERK signaling pathway. Mulberroside C promotes neutrophil maturation, accelerates the recovery of leukopenia, and enhances the antibacterial activity of neutrophils. Mulberroside C inhibits the replication of hepatitis C virus in replicon cells. Mulberroside C prevents the uncoating and genome release of EV-A71, and inhibits the synthesis of viral proteins and RNA. Mulberroside C can be used in studies related to thrombosis-mediated cardiovascular diseases, chemotherapy- and radiotherapy-induced leukopenia, hepatitis C virus infection, and hand, foot and mouth disease .
loading...
    loading...
Cat. No.: HY-155876
CAS No.: 2271394-34-2
Purity:  99.97%
Synonyms: NLRP3 antagonist 2
NVP-DFV890 is an orally administered, selective NLRP3 inhibitor. NVP-DFV890 directly binds to NLRP3, blocks maturation of pro-inflammatory cytokines IL-1β and IL-18, and inhibits pyroptotic cell death. NVP-DFV890 acts as an inducer of viral clearance, promoting earlier clearance of SARS-CoV-2. NVP-DFV890 can be used for the research of COVID-19 pneumonia and coronavirus-associated acute respiratory distress syndrome (CARDS) .
loading...
    loading...
Cat. No.: HY-147020
CAS No.: 2922281-15-8
Purity:  ≥98.0%
Synonyms: NK01-63
Target:  

SARS-CoV

Research Areas:  

Infection

Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .
loading...
    loading...
Cat. No.: HY-19296
CAS No.: 142356-43-2
Synonyms: 2-Bromo-5,6-dichloro-1-β-D-ribofuranosyl benzimidazole
Target:  

CMV

Research Areas:  

Infection

BDCRB is a selective Human cytomegalovirus (HCMV) inhibitor through blocking the maturational cleavage of high-molecular-weight DNA. BDCRB shows a mean IC50 of 0.03 μM for viral yield at 72 h postinfection .
loading...
    loading...
Cat. No.: HY-105448
CAS No.: 112190-24-6
Target:  

HIV Protease

Research Areas:  

Infection

U-75875 is a HIV-1 protease inhibitor. U-75875 can block Gag-Pol protein processing and viral maturation and replication. U-75875 can be used for the research of infection .
loading...
    loading...
Cat. No.: HY-105148
CAS No.: 174391-92-5
Synonyms: DMP-450
Target:  

HIV HIV Protease

Research Areas:  

Infection

Mozenavir (DMP 450) is an orally active and highly selective inhibitor of HIV-1 protease (Ki=0.3 nM). Mozenavir blocks the cleavage and processing of viral polyproteins, inhibiting the replication and maturation of HIV-1. Mozenavir is promising for research of HIV infection .
loading...
    loading...
Cat. No.: HY-117137
CAS No.: 217950-62-4
Target:  

CMV

Research Areas:  

Infection

GW 275175X is an inhibitor of the terminase complex involved in cleavage and packaging of the unit length DNA into the capsids. GW 275175X exhibits long plasma half-life. GW 275175X is a BDCRB derivative. GW 275175X exhibits anti-HCMV activity through inhibiting maturation of viral DNA .
loading...
    loading...
Cat. No.: HY-120764
CAS No.: 1207481-21-7
Target:  

HIV

Research Areas:  

Infection

PF-46396 is a potent HIV-1 inhibitor with an EC50 value of 0.206 µM. PF-46396 shows antiviral activity. PF-46396 inhibits the processing of capsid (CA)/spacer peptide 1 (SP1) (p25) Gag precursor proteins and blocks maturation of the viral core particle .
loading...
    loading...
Cat. No.: HY-174998
CAS No.: 2986573-09-3
Target:  

HIV HIV Protease

Research Areas:  

Infection

HIV-1 protease-IN-15 (Compound 27) is an orally active and selective inhibitor targeting HIV-1 protease with a pIC50 value of 9.347. HIV-1 protease-IN-15 inhibits HIV protein maturation, blocks viral replication. HIV-1 protease-IN-15 is promising for research of HIV-1 infection .
loading...
    loading...
Cat. No.: HY-N0842R
CAS No.: 174022-42-5
Synonyms: PA-457 (Standard); MPC-4326 (Standard); YK FH312 (Standard)
Bevirimat (Standard) is the analytical standard of Bevirimat. This product is intended for research and analytical applications. Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies[1][2][3][4].
loading...
    loading...
Cat. No.: HY-P5415
CAS No.: 127134-13-8
Target:  

HIV

Research Areas:  

Others

DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is a biological active peptide. (DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is also called HIV protease substrate I in some literature. It is widely used for the continuous assay for HIV protease activity. The 11-Kd protease (PR) encoded by the human immunodeficiency virus 1 (HIV-1) is essential for the correct processing of viral polyproteins and the maturation of infectious virus, and is therefore a target for the design of selective acquired immunodeficiency syndrome (AIDS) therapeutics. The FRET-based fluorogenic substrate is derived from a natural processing site for HIV-1 PR. Incubation of recombinant HIV-1 PR with the fluorogenic substrate resulted in specific cleavage at the Tyr-Pro bond and a time-dependent increase in fluorescence intensity that is linearly related to the extent of substrate hydrolysis. The fluorescence quantum yields of the HIV-1 PR substrate in the FRET assay increased by 40.0- and 34.4-fold, respectively, per mole of substrate cleaved. Because of its simplicity and precision in the determination of reaction rates required for kinetic analysis, this substrate offers many advantages over the commonly used HPLC or electrophoresis-based assays for peptide substrate hydrolysis by retroviral PRs. Abs/Em = 340nm/490nm.)
loading...
    loading...
Cat. No.: HY-126120
CAS No.: 154612-31-4
Target:  

HIV HIV Protease

Research Areas:  

Infection

BILA 1906 BS is a HIV protease inhibitor. BILA 1906 BS prevents HIV-1 replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
loading...
    loading...
Cat. No.: HY-127083
CAS No.: 29431-84-3
Artecanin is a SARS-CoV-2 main protease (M pro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of M pro, blocks the cleavage and maturation of viral precursor proteins, and forms a stable complex with M pro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19 .
loading...
    loading...
Cat. No.: HY-183376
CAS No.: 126103-94-4
Target:  

HIV Protease

Research Areas:  

Infection

U 81749 is a competitive, reversible HIV-1 protease inhibitor with a Ki value of 70 nM. U 81749 inhibits HIV-1 protease within HIV-like particles, blocks the processing of the HIV-1 gag polyprotein p55 into the mature structural proteins p24 and p17, and thereby prevents viral maturation. U 81749 reduces HIV p24 and HIV RNA levels in acutely infected human lymphocytes, and shows no toxicity to lymphocyte proliferation at effective concentrations. U 81749 can be used in studies related to HIV-1 infection .
loading...
    loading...
Cat. No.: HY-111964R
CAS No.: 2189684-44-2
Synonyms: GS-6207 (Standard)
Target:  

Reference Standards HIV

Research Areas:  

Infection

Lenacapavir (Standard) is the analytical standard of Lenacapavir (HY-111964). This product is intended for research and analytical applications. Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
loading...
    loading...
Cat. No.: HY-111964S1
Synonyms: GS-6207-d5
Lenacapavir-d5 (GS-6207-d5) is the deuterium labeled Lenacapavir (HY-111964). Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
loading...
    loading...
  • 1